Evidence map›Paper›PMID 33381269›Full record

ArticleOxidative medicine and cellular longevity2020

Ana L de B Oliveira, Kely C Navegantes-Lima, Valter V S Monteiro, Lucas B G Quadros, Juliana P de Oliveira, Sávio M Dos Santos, Anna C A de A Pontes, Gilson P Dorneles, Pedro R T Romão, Luiz C R Júnior and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oxidative medicine and cellular longevity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Lipid Fraction fromAntioxidants (Basel, Switzerland) · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ana L de B OliveiraNeuroscience and Cellular Biology Post-Graduation Program, Biology Science Institute, Federal University of Pará/UFPA, Belém 66075-900, Brazil.
Kely C Navegantes-LimaNeuroscience and Cellular Biology Post-Graduation Program, Biology Science Institute, Federal University of Pará/UFPA, Belém 66075-900, Brazil.
Valter V S MonteiroCenter of Research of Inflammatory Diseases, Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14055230, Brazil.ORCID https://orcid.org/0000-0003-1785-6713
Lucas B G QuadrosSchool of Pharmacy, Health Science Institute, Federal University of Pará/UFPA, Belém 66075-900, Brazil.
Juliana P de OliveiraSchool of Pharmacy, Health Science Institute, Federal University of Pará/UFPA, Belém 66075-900, Brazil.
Sávio M Dos SantosPharmaceutical Sciences Post-Graduation Program, Institute of Health Sciences, Federal University of Pará/UFPA, Belém 66075-900, Brazil.
Anna C A de A PontesPharmaceutical Sciences Post-Graduation Program, Institute of Health Sciences, Federal University of Pará/UFPA, Belém 66075-900, Brazil.
Gilson P DornelesLaboratory of Cellular and Molecular Immunology, Department of Basic Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, Brazil.ORCID https://orcid.org/0000-0001-6524-3204
Pedro R T RomãoLaboratory of Cellular and Molecular Immunology, Department of Basic Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, Brazil.
Luiz C R JúniorLaboratory of Cellular and Molecular Immunology, Department of Basic Health Sciences, Federal University of Health Sciences of Porto Alegre, Porto Alegre 90050-170, Brazil.
Alaíde B de OliveiraDepartment of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
Marta C MonteiroNeuroscience and Cellular Biology Post-Graduation Program, Biology Science Institute, Federal University of Pará/UFPA, Belém 66075-900, Brazil.ORCID https://orcid.org/0000-0002-3328-5650
Universidade Federal do Pará · BRUniversidade de São Paulo · BRUniversidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is characterized by a dysregulated immune response to infection characterized by an early hyperinflammatory and oxidative response followed by a subsequent immunosuppression phase. Although there have been some advances in the treatment of sepsis, mortality rates remain high, urging for the search of new therapies.

Indexed as

AnimalsAnti-Inflammatory AgentsChemopreventionCytokinesDisease Models, AnimalImmunosuppression TherapyInflammationInflammation MediatorsMaleMiceNaphthoquinonesOxidative StressSepsisSurvival RateAnti-Inflammatory Agentsbeta-lapachoneCytokinesInflammation MediatorsNaphthoquinones

Identifiers

PMID33381269
PMCPMC7749764
OpenAlexW3110786308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.